Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07585136

PHASE1

Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders

Sponsor: St. Jude Children's Research Hospital

View on ClinicalTrials.gov

Summary

The purpose of this study is to investigate mobilization and collection of HSPCs in patients with bone marrow failure syndromes (BMFS) using granulocyte-colony stimulating factor (otherwise known as Filgrastim) with plerixafor to demonstrate safety and feasibility of collecting HSPCs to advance gene therapy. Primary objective: \- To characterize the safety of Filgrastim plus plerixafor in participants with bone marrow failure syndromes as determined by the incidence of adverse events (AEs). Secondary Objectives: * To characterize the feasibility of HSPC mobilization using Filgrastim plus plerixafor as determined by peripheral blood CD34+ counts. * To measure the mobilization effects of Filgrastim plus plerixafor in the peripheral blood in participants as determined by peak peripheral blood CD34+ counts. * To estimate efficacy of Filgrastim plus plerixafor for HSPC mobilization and apheresis collection in participants as determined by the yield of CD34+ cells (CD34+ cells/kg).

Key Details

Gender

All

Age Range

18 Years - 25 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2026-06

Completion Date

2029-07-01

Last Updated

2026-05-13

Healthy Volunteers

Conditions

Bone Marrow Failure Syndrome

Interventions

DRUG

Filgrastim

Administered twice daily dose starting on day 1 for 5 days.

DRUG

Plerixafor

Administered on day 5 via IV.

PROCEDURE

Leukapheresis

Peripheral venous access or through a central venous catheter approximately 4-5 hours after the dose of plerixafor is given.

Inclusion Criteria: * Participants with a bone marrow failure syndrome with an identified genetic cause willing to donate autologous HSPCs for advancing gene therapy * Age ≥ 18 years - 25 years * The following hematological parameters need to be met (regardless of transfusion or growth factor support) * Hb \> 8 g/dL * ANC \> 500/mm3 * Platelet \> 30,000/mm3 * Bone marrow evaluation within the preceding 6 months prior to mobilization and apheresis * Participants should either have a central venous catheter (CVC) in place, be able to undergo apheresis without requiring a CVC, or agree to having a temporary apheresis catheter placed * Karnofsky score \>80 * Negative serologic tests for syphilis, hepatitis B and C, HIV, and HTLV-1/II * Female participants of childbearing age should have a negative serum pregnancy test within one week of beginning Filgrastim and plerixafor administration Exclusion Criteria: * Participant with sickle cell disease * Participant who has had a prior autologous or allogeneic HSCT * Active viral, bacterial, fungal, or parasitic infection * Total bilirubin \>2.5x ULN or transaminases \>5x ULN * Moderate or severe renal failure defined as serum/plasma creatinine \>1.5 mg/dL and an estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2 based on the CKD-Epi equation or the St. Jude equation * Diagnosis of MDS or other hematologic malignancy * History of malignancy * Known allergy to or contraindication for Filgrastim or plerixafor administration, or medications routinely administered during apheresis * Splenomegaly (size greater than upper limit of normal on examination) * Any disease or concomitant process that is not compatible with the study as per investigator opinion * Concomitant treatment with alternative investigational agent or participation in another clinical trial with an investigational drug within 5 half-lives of the investigational agent * Unwillingness to use a highly effective method of contraception for 1 month after plerixafor or GCSF * Pregnancy * Inability or unwillingness of research participant to give written informed consent.

Locations (1)

Saint Jude Children's Research Hospital

Memphis, Tennessee, United States